|
1
|
Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials.
|
JAMA
|
1998
|
4.99
|
|
2
|
A controlled trial of early versus late treatment with zidovudine in symptomatic human immunodeficiency virus infection. Results of the Veterans Affairs Cooperative Study.
|
N Engl J Med
|
1992
|
3.34
|
|
3
|
Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity.
|
Antimicrob Agents Chemother
|
2008
|
3.09
|
|
4
|
Daptomycin: a novel agent for Gram-positive infections.
|
Expert Opin Investig Drugs
|
1999
|
2.83
|
|
5
|
Pharmacodynamics of fluconazole in a murine model of systemic candidiasis.
|
Antimicrob Agents Chemother
|
1998
|
2.59
|
|
6
|
Effect of 2',3'-didehydro-3'-deoxythymidine in an in vitro hollow-fiber pharmacodynamic model system correlates with results of dose-ranging clinical studies.
|
Antimicrob Agents Chemother
|
1994
|
2.46
|
|
7
|
Emergence of resistance to imipenem in Pseudomonas aeruginosa.
|
Antimicrob Agents Chemother
|
1987
|
2.44
|
|
8
|
Postantibiotic effect of imipenem on Pseudomonas aeruginosa.
|
Antimicrob Agents Chemother
|
1984
|
2.43
|
|
9
|
Pharmacodynamics of daptomycin in a murine thigh model of Staphylococcus aureus infection.
|
Antimicrob Agents Chemother
|
2001
|
2.24
|
|
10
|
A 24-week open-label phase I/II evaluation of the HIV protease inhibitor MK-639 (indinavir).
|
AIDS
|
1996
|
2.03
|
|
11
|
Multiple-dose pharmacokinetics of imipenem-cilastatin.
|
Antimicrob Agents Chemother
|
1984
|
1.98
|
|
12
|
Absolute oral bioavailability of ciprofloxacin.
|
Antimicrob Agents Chemother
|
1986
|
1.97
|
|
13
|
Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity.
|
Antimicrob Agents Chemother
|
1999
|
1.90
|
|
14
|
Human serum alpha 1 acid glycoprotein reduces uptake, intracellular concentration, and antiviral activity of A-80987, an inhibitor of the human immunodeficiency virus type 1 protease.
|
Antimicrob Agents Chemother
|
1996
|
1.89
|
|
15
|
Optimizing aminoglycoside therapy for nosocomial pneumonia caused by gram-negative bacteria.
|
Antimicrob Agents Chemother
|
1999
|
1.77
|
|
16
|
In vivo pharmacodynamics of torezolid phosphate (TR-701), a new oxazolidinone antibiotic, against methicillin-susceptible and methicillin-resistant Staphylococcus aureus strains in a mouse thigh infection model.
|
Antimicrob Agents Chemother
|
2011
|
1.75
|
|
17
|
Levofloxacin population pharmacokinetics and creation of a demographic model for prediction of individual drug clearance in patients with serious community-acquired infection.
|
Antimicrob Agents Chemother
|
1998
|
1.73
|
|
18
|
Impact of drug-exposure intensity and duration of therapy on the emergence of Staphylococcus aureus resistance to a quinolone antimicrobial.
|
J Infect Dis
|
2007
|
1.70
|
|
19
|
Effective antimicrobial regimens for use in humans for therapy of Bacillus anthracis infections and postexposure prophylaxis.
|
Antimicrob Agents Chemother
|
2005
|
1.69
|
|
20
|
The acylampicillins: mezlocillin, piperacillin, and azlocillin.
|
Rev Infect Dis
|
1984
|
1.48
|
|
21
|
Multiple-dose pharmacokinetics of ciprofloxacin administered intravenously to normal volunteers.
|
Antimicrob Agents Chemother
|
1985
|
1.46
|
|
22
|
Pharmacodynamics of β-lactamase inhibition by NXL104 in combination with ceftaroline: examining organisms with multiple types of β-lactamases.
|
Antimicrob Agents Chemother
|
2011
|
1.46
|
|
23
|
Fluoroquinolone pharmacodynamics.
|
Clin Infect Dis
|
2001
|
1.45
|
|
24
|
Reduction of the in vitro activity of A77003, an inhibitor of human immunodeficiency virus protease, by human serum alpha 1 acid glycoprotein.
|
J Infect Dis
|
1995
|
1.43
|
|
25
|
Penetration of meropenem into epithelial lining fluid of patients with ventilator-associated pneumonia.
|
Antimicrob Agents Chemother
|
2011
|
1.35
|
|
26
|
Integration of selected pharmacologic and microbiologic properties of three new beta-lactam antibiotics: a hypothesis for rational comparison.
|
Rev Infect Dis
|
1984
|
1.33
|
|
27
|
Systematic comparison of the population pharmacokinetics and pharmacodynamics of piperacillin in cystic fibrosis patients and healthy volunteers.
|
Antimicrob Agents Chemother
|
2007
|
1.33
|
|
28
|
Comparison of the pharmacokinetics of ceftazidime and moxalactam and their microbiological correlates in volunteers.
|
Antimicrob Agents Chemother
|
1984
|
1.31
|
|
29
|
An overview of the pharmacology of imipenem/cilastatin.
|
J Antimicrob Chemother
|
1986
|
1.31
|
|
30
|
A prospective randomized controlled trial of cefoxitin versus clindamycin-aminoglycoside in mixed anaerobic-aerobic infections.
|
Surg Gynecol Obstet
|
1982
|
1.28
|
|
31
|
Pharmacokinetic profile of imipenem/cilastatin in normal volunteers.
|
Am J Med
|
1985
|
1.28
|
|
32
|
The combination of meropenem and levofloxacin is synergistic with respect to both Pseudomonas aeruginosa kill rate and resistance suppression.
|
Antimicrob Agents Chemother
|
2010
|
1.27
|
|
33
|
Population pharmacokinetics of zidovudine. The Veterans Administration Cooperative Studies Group.
|
Clin Pharmacol Ther
|
1990
|
1.25
|
|
34
|
Pharmacodynamic evaluation of extending the administration time of meropenem using a Monte Carlo simulation.
|
Antimicrob Agents Chemother
|
2005
|
1.24
|
|
35
|
Dose ranging study and constant infusion evaluation of ciprofloxacin.
|
Antimicrob Agents Chemother
|
1986
|
1.23
|
|
36
|
Pharmacokinetic studies of fluconazole in rabbits characterizing doses which achieve peak levels in serum and area under the concentration-time curve values which mimic those of high-dose fluconazole in humans.
|
Antimicrob Agents Chemother
|
1998
|
1.23
|
|
37
|
Effect of dose size on bioavailability of ciprofloxacin.
|
Antimicrob Agents Chemother
|
1987
|
1.22
|
|
38
|
Antifungal pharmacokinetics and pharmacodynamics: bridging from the bench to bedside.
|
Clin Microbiol Infect
|
2009
|
1.22
|
|
39
|
Preclinical evaluation of antiviral activity and toxicity of Abbott A77003, an inhibitor of the human immunodeficiency virus type 1 protease.
|
Antimicrob Agents Chemother
|
1993
|
1.21
|
|
40
|
Pharmacokinetics and absolute bioavailability of ribavirin in healthy volunteers as determined by stable-isotope methodology.
|
Antimicrob Agents Chemother
|
1999
|
1.21
|
|
41
|
Efficacy of constant infusion of A-77003, an inhibitor of the human immunodeficiency virus type 1 (HIV-1) protease, in limiting acute HIV-1 infection in vitro.
|
Antimicrob Agents Chemother
|
1995
|
1.20
|
|
42
|
Imipenem coadministered with cilastatin compared with moxalactam: integration of serum pharmacokinetics and microbiologic activity following single-dose administration to normal volunteers.
|
Antimicrob Agents Chemother
|
1986
|
1.18
|
|
43
|
Pharmacokinetics of intravenously administered ciprofloxacin in patients with various degrees of renal function.
|
Antimicrob Agents Chemother
|
1987
|
1.17
|
|
44
|
Pharmacodynamics of levofloxacin in a murine pneumonia model of Pseudomonas aeruginosa infection: determination of epithelial lining fluid targets.
|
Antimicrob Agents Chemother
|
2009
|
1.16
|
|
45
|
Use of an in vitro pharmacodynamic model to derive a linezolid regimen that optimizes bacterial kill and prevents emergence of resistance in Bacillus anthracis.
|
Antimicrob Agents Chemother
|
2008
|
1.14
|
|
46
|
Meropenem pharmacokinetics in the newborn.
|
Antimicrob Agents Chemother
|
2009
|
1.10
|
|
47
|
The plasma pharmacokinetics of high dose (1 g) imipenem coadministered with 1 g cilastatin in six normal volunteers.
|
Eur J Clin Microbiol
|
1984
|
1.08
|
|
48
|
Identifying exposure targets for treatment of staphylococcal pneumonia with ceftobiprole.
|
Antimicrob Agents Chemother
|
2009
|
1.07
|
|
49
|
Efficacies of high-dose fluconazole plus amphotericin B and high-dose fluconazole plus 5-fluorocytosine versus amphotericin B, fluconazole, and 5-fluorocytosine monotherapies in treatment of experimental endocarditis, endophthalmitis, and pyelonephritis due to Candida albicans.
|
Antimicrob Agents Chemother
|
1999
|
1.06
|
|
50
|
Identification of optimal renal dosage adjustments for traditional and extended-infusion piperacillin-tazobactam dosing regimens in hospitalized patients.
|
Antimicrob Agents Chemother
|
2009
|
1.05
|
|
51
|
Feedback dose alteration significantly affects probability of pathogen eradication in nosocomial pneumonia.
|
Eur Respir J
|
2009
|
1.03
|
|
52
|
Lactobacillus prophylaxis for diarrhea due to enterotoxigenic Escherichia coli.
|
Antimicrob Agents Chemother
|
1981
|
1.03
|
|
53
|
Synergism of the combinations of imipenem plus ciprofloxacin and imipenem plus amikacin against Pseudomonas aeruginosa and other bacterial pathogens.
|
Antimicrob Agents Chemother
|
1987
|
1.03
|
|
54
|
Rapid ganciclovir susceptibility assay using flow cytometry for human cytomegalovirus clinical isolates.
|
Antimicrob Agents Chemother
|
1998
|
1.03
|
|
55
|
Optimal sampling schedule design for populations of patients.
|
Antimicrob Agents Chemother
|
2003
|
1.03
|
|
56
|
Impact of different carbapenems and regimens of administration on resistance emergence for three isogenic Pseudomonas aeruginosa strains with differing mechanisms of resistance.
|
Antimicrob Agents Chemother
|
2010
|
1.03
|
|
57
|
In vitro susceptibility of pathogenic Vibrio species to norfloxacin and six other antimicrobial agents.
|
Antimicrob Agents Chemother
|
1985
|
1.02
|
|
58
|
Pharmacokinetics and pharmacodynamics: optimal antimicrobial therapy in the intensive care unit.
|
Crit Care Clin
|
2011
|
1.02
|
|
59
|
Comparative pharmacokinetics and pharmacodynamic target attainment of ertapenem in normal-weight, obese, and extremely obese adults.
|
Antimicrob Agents Chemother
|
2006
|
1.01
|
|
60
|
Interaction between fluconazole and amphotericin B in mice with systemic infection due to fluconazole-susceptible or -resistant strains of Candida albicans.
|
Antimicrob Agents Chemother
|
1999
|
1.01
|
|
61
|
Impact of dosing schedule upon suppression of a retrovirus in a murine model of AIDS encephalopathy.
|
Antimicrob Agents Chemother
|
1994
|
1.00
|
|
62
|
Multiple-dose ciprofloxacin dose ranging and kinetics.
|
Clin Pharmacol Ther
|
1985
|
1.00
|
|
63
|
Population pharmacokinetics of extended-infusion piperacillin-tazobactam in hospitalized patients with nosocomial infections.
|
Antimicrob Agents Chemother
|
2012
|
1.00
|
|
64
|
Pharmacokinetic evaluation of two dosage regimens of clindamycin phosphate.
|
Antimicrob Agents Chemother
|
1989
|
1.00
|
|
65
|
Cefoxitin falsely elevates creatinine levels.
|
JAMA
|
1982
|
1.00
|
|
66
|
Flow cytometric determination of ganciclovir susceptibilities of human cytomegalovirus clinical isolates.
|
J Clin Microbiol
|
1998
|
1.00
|
|
67
|
Comparative pharmacokinetics of moxalactam, cefoperazone, and cefotaxime in normal volunteers.
|
Rev Infect Dis
|
1983
|
1.00
|
|
68
|
Bactericidal activity of ceftazidime in serum compared with that of ticarcillin combined with amikacin.
|
Antimicrob Agents Chemother
|
1984
|
0.99
|
|
69
|
An overview of the pharmacology of intravenously administered ciprofloxacin.
|
Am J Med
|
1987
|
0.97
|
|
70
|
Potential of imipenem as single-agent empiric antibiotic therapy of febrile neutropenic patients with cancer.
|
Am J Med
|
1985
|
0.96
|
|
71
|
Use of pharmacokinetic/pharmacodynamic systems analyses to inform dose selection of tedizolid phosphate.
|
Clin Infect Dis
|
2014
|
0.96
|
|
72
|
Prospective use of optimal sampling theory: steady-state ciprofloxacin pharmacokinetics in critically ill trauma patients.
|
Clin Pharmacol Ther
|
1989
|
0.94
|
|
73
|
Impact of meropenem in combination with tobramycin in a murine model of Pseudomonas aeruginosa pneumonia.
|
Antimicrob Agents Chemother
|
2013
|
0.93
|
|
74
|
A double beta-lactam combination versus an aminoglycoside-containing regimen as empiric antibiotic therapy for febrile granulocytopenic cancer patients.
|
Am J Med
|
1986
|
0.93
|
|
75
|
Relevance of plasma protein binding to antiviral activity and clinical efficacy of inhibitors of human immunodeficiency virus protease.
|
J Infect Dis
|
1996
|
0.93
|
|
76
|
Effect of coadministration of moxifloxacin and rifampin on Mycobacterium tuberculosis in a murine aerosol infection model.
|
Antimicrob Agents Chemother
|
2012
|
0.93
|
|
77
|
Efficacy of ciprofloxacin in the treatment of chronic typhoid carriers.
|
J Infect Dis
|
1988
|
0.91
|
|
78
|
Long-term follow-up of symptomatic HIV-infected patients originally randomized to early versus later zidovudine treatment; report of a Veterans Affairs Cooperative Study. VA Cooperative Study Group on AIDS Treatment.
|
J Acquir Immune Defic Syndr Hum Retrovirol
|
1996
|
0.90
|
|
79
|
Pharmacodynamics of ceftazidime and meropenem in cerebrospinal fluid: results of population pharmacokinetic modelling and Monte Carlo simulation.
|
J Antimicrob Chemother
|
2007
|
0.90
|
|
80
|
Emergence of resistance to carbapenem antibiotics in Pseudomonas aeruginosa.
|
J Antimicrob Chemother
|
1989
|
0.89
|
|
81
|
Effect of saturable clearance during high-dose mezlocillin therapy.
|
Antimicrob Agents Chemother
|
1984
|
0.89
|
|
82
|
Susceptibilities of human cytomegalovirus clinical isolates to BAY38-4766, BAY43-9695, and ganciclovir.
|
Antimicrob Agents Chemother
|
2001
|
0.89
|
|
83
|
Population pharmacokinetic comparison and pharmacodynamic breakpoints of ceftazidime in cystic fibrosis patients and healthy volunteers.
|
Antimicrob Agents Chemother
|
2010
|
0.88
|
|
84
|
Modeling of the change in CD4 lymphocyte counts in patients before and after administration of the human immunodeficiency virus protease inhibitor indinavir.
|
Antimicrob Agents Chemother
|
1997
|
0.88
|
|
85
|
Use of an in vitro pharmacodynamic model to derive a moxifloxacin regimen that optimizes kill of Yersinia pestis and prevents emergence of resistance.
|
Antimicrob Agents Chemother
|
2010
|
0.88
|
|
86
|
Improved micromethod for mezlocillin quantitation in serum and urine by high-pressure liquid chromatography.
|
Antimicrob Agents Chemother
|
1984
|
0.88
|
|
87
|
Natural history of Yersinia pestis pneumonia in aerosol-challenged BALB/c mice.
|
Antimicrob Agents Chemother
|
2013
|
0.88
|
|
88
|
Cefoxitin-resistant facultative or aerobic gram-negative bacilli in infections associated with the gastrointestinal tract.
|
Ann Intern Med
|
1981
|
0.88
|
|
89
|
Steady-state serum pharmacokinetics of novobiocin and rifampin alone and in combination.
|
Antimicrob Agents Chemother
|
1986
|
0.88
|
|
90
|
Population differences in ganciclovir clearance as determined by nonlinear mixed-effects modelling.
|
Antimicrob Agents Chemother
|
1995
|
0.87
|
|
91
|
Comparative pharmacokinetics and serum bactericidal activity of mezlocillin, ticarcillin and piperacillin, with and without gentamicin.
|
J Antimicrob Chemother
|
1985
|
0.86
|
|
92
|
Relationships between renal function and disposition of oral ciprofloxacin.
|
Antimicrob Agents Chemother
|
1988
|
0.86
|
|
93
|
Impact of different factors on the probability of clinical response in tigecycline-treated patients with intra-abdominal infections.
|
Antimicrob Agents Chemother
|
2009
|
0.86
|
|
94
|
Bactericidal activity of ciprofloxacin compared with that of cefotaxime in normal volunteers.
|
Antimicrob Agents Chemother
|
1987
|
0.86
|
|
95
|
The triple combination indinavir-zidovudine-lamivudine is highly synergistic.
|
Antimicrob Agents Chemother
|
2000
|
0.85
|
|
96
|
Moxalactam and piperacillin: a study of in vitro characteristics and pharmacokinetics in cancer patients.
|
Infection
|
1985
|
0.84
|
|
97
|
Soluble tumor necrosis factor-alpha receptor type II (sTNF alpha RII) correlates with human immunodeficiency virus (HIV) RNA copy number in HIV-infected patients.
|
J Infect Dis
|
1996
|
0.84
|
|
98
|
Aqueous and vitreous penetration of ciprofloxacin following different modes of systemic administration.
|
Exp Eye Res
|
1996
|
0.84
|
|
99
|
Dosing adjustment of 10 antimicrobials for patients with renal impairment.
|
Ann Pharmacother
|
1995
|
0.84
|
|
100
|
Pharmacokinetics of ceftazidime, alone or in combination with piperacillin or tobramycin, in the sera of cancer patients.
|
Antimicrob Agents Chemother
|
1985
|
0.82
|
|
101
|
How does a patient maximally benefit from anti-infective chemotherapy?
|
Clin Infect Dis
|
2004
|
0.82
|
|
102
|
How many steps along the path is too far?
|
Clin Infect Dis
|
2010
|
0.81
|
|
103
|
Future trends in antimicrobial chemotherapy: expert opinion on the 43rd ICAAC.
|
J Chemother
|
2004
|
0.80
|
|
104
|
Use of human renal proximal tubule cell cultures for studying foscarnet-induced nephrotoxicity in vitro.
|
Antimicrob Agents Chemother
|
1993
|
0.80
|
|
105
|
Effect of renal function on the bioavailability of ciprofloxacin.
|
Antimicrob Agents Chemother
|
1990
|
0.79
|
|
106
|
Serum bactericidal test in volunteers--a review.
|
Eur J Clin Microbiol
|
1986
|
0.78
|
|
107
|
Safety and tolerability of multiple doses of imipenem/cilastatin.
|
Clin Pharmacol Ther
|
1985
|
0.78
|
|
108
|
Nonparametric expectation maximization population modeling of ganciclovir.
|
J Clin Pharmacol
|
1996
|
0.77
|
|
109
|
Saving lives with optimal antimicrobial chemotherapy.
|
Clin Infect Dis
|
2012
|
0.77
|
|
110
|
Comparison of the probability of target attainment between ceftriaxone and cefepime in the cerebrospinal fluid and serum against Streptococcus pneumoniae.
|
Diagn Microbiol Infect Dis
|
2007
|
0.76
|
|
111
|
Determination of meropenem penetration into the lung from Sparse data.
|
Antimicrob Agents Chemother
|
2011
|
0.75
|
|
112
|
Double-blind, prospective, multicenter trial comparing ceftazidime with moxalactam in the treatment of serious gram-negative infections.
|
Antimicrob Agents Chemother
|
1986
|
0.75
|
|
113
|
Hollow-fiber pharmacodynamic studies and mathematical modeling to predict the efficacy of amoxicillin for anthrax postexposure prophylaxis in pregnant women and children.
|
Antimicrob Agents Chemother
|
2013
|
0.75
|
|
114
|
Measurement of amikacin in serum by a latex agglutination inhibition test.
|
J Clin Microbiol
|
1985
|
0.75
|
|
115
|
Acute thrombocytopenia secondary to the administration of the peptidomimetic HIV protease inhibitor MK-639(L735524)
|
AIDS
|
1996
|
0.75
|
|
116
|
False elevation in serum creatinine levels.
|
JAMA
|
1984
|
0.75
|
|
117
|
The serum bactericidal activity of latamoxef (moxalactam), cefoperazone and cefotaxime.
|
J Antimicrob Chemother
|
1984
|
0.75
|
|
118
|
Lack of interference with creatinine assays by four cephalosporin-like antibiotics.
|
Am J Clin Pathol
|
1984
|
0.75
|
|
119
|
Pseudomonas meningitis therapy recommendation questioned.
|
Pediatrics
|
1989
|
0.75
|
|
120
|
Use of nonlinear, mixed-effects modeling for population analysis of ofloxacin: effects of age on oral drug pharmacokinetics.
|
Pharmacotherapy
|
1992
|
0.75
|
|
121
|
Ciprofloxacin pharmacokinetics in critically ill trauma patients.
|
Am J Med
|
1989
|
0.75
|
|
122
|
Serum inhibitory and bactericidal activity against methicillin-resistant Staphylococcus aureus in volunteers receiving novobiocin and rifampin alone and in combination.
|
Diagn Microbiol Infect Dis
|
1994
|
0.75
|